ШКАЛЫ ПРОГНОЗА СЕРДЕЧНО-СОСУДИСТЫХ ЗАБОЛЕВАНИЙ
https://doi.org/10.20514/2226-6704-2015-0-5-11
Аннотация
В статье обсуждается оценка прогноза сердечно-сосудистых заболеваний с помощью специальных шкал. Рассмотрены преимущества и ограничения использования шкал в практике кардиолога. Автором разработана программа «КардиоЭксперт» для мобильных устройств, которая включает набор наиболее востребованных шкал прогноза сердечно-сосудистых заболеваний и калькуляторов.
Об авторе
Ф. И. Белялов
ГБОУ ДПО «Иркутская государственная медицинская академия последипломного образования»
Россия
Россия
кафедра геронтологии и гериатрии,
Иркутск
Список литературы
1. Fibrillation. J. Am. Coll. Cardiol. 2014; 64: e1–e76.
2. 2014 AHA/ACC Guideline for the Management of Patients With Non—ST-Elevation Acute Coronary Syndromes. Circulation. 2014; 130: e344–426.
3. Burgess S., Crown N., Louzada M.L. et al. Clinical performance of bleeding risk scores for predicting major and clinically relevant non-major bleeding events in patients receiving warfarin. J. Thromb. Haemost. 2013; 11: 1647–1654.
4. Chao T., Wang K., Liu C. et al. Age Threshold for Increased Stroke Risk Among Patients With Atrial Fibrillation: A Nationwide Cohort Study From Taiwan. J. Am. Coll. Cardiol. 2015; 66: 1339–1347.
5. Fox K.A.A., FitzGerald G., Puymirat E. et al. Should patients with acute coronary disease be stratified for management according to their risk? Derivation, external validation and outcomes using the updated GRACE risk score. BMJ Open. 2014; 4(2): e004425.
6. Genders T.S.S., Steyerberg E.W., Hunink M.M.G. et al. Prediction model to estimate presence of coronary artery disease: retrospective pooled analysis of existing cohorts. BMJ. 2012; 344: e3485.
7. Goto S., Zhu J., Liu L. et al. Efficacy and Safety of Apixaban Compared with Warfarin for Stroke Prevention in Patients with Atrial Fibrillation from East Asia // American heart journal. 2014; 168: 303–309.
8. Hobbs F.D.R., Roalfe A.K., Lip G.Y.H. et al. Performance of stroke risk scores in older people with atrial fibrillation not taking warfarin: comparative cohort study from BAFTA trial. BMJ. 2011; 342: d3653.
9. Hosmer D.W., Lemeshow S. Applied Logistic Regression. 2nd ed. New York, NY: John Wiley & Sons. 2000.
10. Huang D.U.O., Anguo L.U.O., Yue W.-S. et al. Refinement of Ischemic Stroke Risk in Patients with Atrial Fibrillation and CHA2DS2-VASc Score of 1. Pacing and Clinical Electrophysiology. 2014; 37: 1442–1447.
11. Koliscak L., Maynor L. Pharmacologic prophylaxis against venous thromboembolism in hospitalized patients with cirrhosis and associated coagulopathies. Am. J. Health Syst. Pharm. 2012; 69: 658–663.
12. Lip G.Y.H. et al. The value of the ESC guidelines for refining stroke risk stratification in patients with atrial fibrillation categorized as low risk using the anticoagulation and risk factors in atrial fibrillation stroke score. Chest. 2014; 146: 1337–1346.
13. Loewen P., Dahri K. Risk of bleeding with oral anticoagulants: an updated systematic review and performance analysis of clinical prediction rules. Ann. Hematol. 2011; 90: 1191–1200.
14. Morris A., Ferdinand K.C. Hyperlipidemia in Racial/Ethnic Minorities: Differences in Lipid Profiles and the Impact of Statin Therapy. Clin. Lipidology. 2009; 4: 741–754.
15. Palaniappan L.P., Araneta M.R.G., Assimes T.L. et al. Call to Action: Cardiovascular Disease in Asian Americans: A Science Advisory From the American Heart Association. Circulation. 2010; 122: 1242–1252.
16. Patel M.R., Dai D., Hernandez A.F. et al. Prevalence and predictors of n onobstructive coronary artery disease identified with coronary angiography in contemporary clinical practice. American heart journal. 2014; 167: 846–852.
17. Pryor D.B., Shaw L., McCants C.B. et al. Value of the history and physical in identifying patients at increased risk for coronary artery disease. Ann. Intern. Med. 1993; 118: 81–90.
18. Simms A.D., Reynolds S., Pieper K. et al. Evaluation of the NICE mini-GRACE risk scores for acute myocardial infarction using the Myocardial Ischaemia National Audit Project (MINAP) 2003-2009. Heart. 2013; 99: 35-40.
19. Stamm J.A., Long J.L., Kirchner H.L., et al. Risk stratification in acute pulmonary embolism: frequency and impact on treatment decisions and outcomes. South. Med. J. 2014; 107: 72–78.
20. Steinberg B.A., Kim S., Thomas L. et al. Lack of Concordance Between Empirical Scores and Physician Assessments of Stroke and Bleeding Risk in Atrial Fibrillation: Results From the ORBIT-AF Registry. Circulation. 2014; 129: 2005–2012.
21. Stroke Risk in Atrial Fibrillation Working Group. Comparison of 12 Risk Stratification Schemes to Predict Stroke in Patients With Nonvalvular Atrial Fibrillation. Stroke. 2008; 39: 1901–1910.
22. Subherwal S., Bach R.G., Chen A.Y. et al. Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: the CRUSADE bleeding score. Circulation. 2009; 119: a1873–1882.
Рецензия
Для цитирования:
Белялов Ф.И. ШКАЛЫ ПРОГНОЗА СЕРДЕЧНО-СОСУДИСТЫХ ЗАБОЛЕВАНИЙ. Архивъ внутренней медицины. 2015;(5):19-21. https://doi.org/10.20514/2226-6704-2015-0-5-11
For citation:
Belyalov F.I. PROGNOSTIC SCORES FOR CARDIOVASCULAR DISEASES. The Russian Archives of Internal Medicine. 2015;(5):19-21. (In Russ.) https://doi.org/10.20514/2226-6704-2015-0-5-11
Просмотров: 1192
Послать статью по эл. почте 